PBM and partner concentration
A limited number of PBMs generate a significant portion of discounted prices and revenue.
- Scope
- Three largest PBM customers accounted for 22% of revenue in 2025
- Materiality
- high
GoodRx Holdings, Inc.
GoodRx Holdings, Inc. operates a consumer healthcare platform that helps Americans compare prescription prices, access discount pricing, and manage medication affordability. The company monetizes traffic through prescription transaction fees, subscription offerings, and pharma manufacturer solutions, while also expanding into telehealth and other healthcare services.
21,7 %
3,8 %
+0,6 %
2.61
2.61
| % | |
|---|---|
| Prescription transactions | 72% Consumer prescription pricing, discount codes, and transaction-based savings at pharmacies. |
| Subscription services | 10% Paid consumer plans such as GoodRx Gold that provide enhanced medication savings. |
| Pharma manufacturer solutions | 18% Commercial services for drug makers, including patient access and affordability programs. |
GoodRx sells to consumers seeking lower out-of-pocket prescription costs, but its commercial relationships also span...
- Consumersprimary
Individuals using GoodRx to compare prices, access discount codes, and save on prescriptions.
- Pharmacy Benefit Managers (PBMs)primary
PBMs provide cash-network pricing and discounts that GoodRx routes to consumers to generate transactions.
- Retail pharmaciesprimary
Pharmacies partner with GoodRx to reduce walk-away patients and increase prescription volume.
- Pharmaceutical manufacturerssecondary
Drug makers buy access and affordability solutions to support patient uptake and adherence.
- Healthcare providers and telehealth userssecondary
Providers and patients use adjacent digital tools and telehealth offerings tied to the platform.
GoodRx generates all of its revenue in the United States, and its platform is built around U.S...
- •All revenue is generated in the United States
- •Business depends on U.S. pharmacy networks and PBM contracts
- •Exposure is tied to U.S. healthcare pricing and reimbursement rules
- •Retail pharmacy store closures can reduce transaction volume
- •Regulatory changes in U.S. healthcare can affect pricing and demand
GoodRx is focused on expanding from prescription savings into a broader consumer healthcare platform while increasing...
01
Expand multi-product adoptionmedium-term
Using more offerings per consumer raises lifetime value without proportionate acquisition cost.
02
Strengthen partner ecosystemmedium-term
PBMs, pharmacies, and manufacturers are core to pricing, traffic, and monetization.
03
Grow pharma manufacturer solutionsshort-term
This segment is growing faster and can diversify revenue away from consumer transaction dependence.
04
Improve brand awarenesslong-term
Awareness is a key barrier to adoption in a consumer healthcare market with many alternatives.
GoodRx depends on a limited set of PBMs, pharmacies, and transaction-processing vendors, so partner concentration and...
Retail pharmacy disruption
Store closures and volume declines reduce prescription transactions processed through the platform.
- Scope
- Broader retail pharmacy landscape changes
- Materiality
- high
U.S. healthcare regulation
Federal and state changes to healthcare spending and medication pricing can alter the economics of the platform.
- Scope
- Prescription affordability and pricing transparency business model
- Materiality
- high
Competition and consumer awareness
The company says awareness is a primary barrier to adoption, so rivals can limit growth.
- Scope
- Consumer internet and healthcare savings tools
- Materiality
- medium
Platform and cybersecurity risk
The business relies on apps, websites, pricing data, and transaction processing infrastructure.
- Scope
- Digital healthcare platform operations
- Materiality
- medium
Revenue recognition by stream
Prescription transactions, subscriptions, and pharma manufacturer solutions
Subscription churn and plan sunsets
GoodRx Gold and other subscription offerings
Business combination accounting
VCRx acquisition and future strategic acquisitions
Capitalized software development
Product development and technology spending
Debt and restricted net assets
Parent company liquidity and capital allocation
Xeris Biopharma Holdings, Inc.
XERS · Pharmaceutical Preparations
Scilex Holding Co
SCLX · Biological Products, (No Diagnostic Substances)
Scilex Holding Co is a U.S.-based biopharmaceutical company focused on non-opioid pain management and other specialty pharmaceutical products.
LadRx Corp
Biological Products, (No Diagnostic Substances)
LadRx Corp is a Delaware-based biopharmaceutical research company focused on oncology drug discovery and clinical development.
HARROW, INC.
HROW · Pharmaceutical Preparations
CANNAPHARMARX, INC.
CPMD · Pharmaceutical Preparations
iRhythm Holdings, Inc.
IRTC · Surgical & Medical Instruments & Apparatus
: 28.4.2026